Jun. 17 at 3:03 PM
$IMAB The HC Wainright presentation was informative this morning. Givastomab is very promising. Low toxicity vs. other drugs. Frontline Claudin represent a
$12 billion market. They talked about other potential uses down the road, including Pancreatic cancer. The big reveal of data is on July 2nd at ESMO presentation.
$168 million in cash on balance sheet at the end of the 1st quarter. Important financial clinical readouts in the next six to twelve months.
Notable quote about upcoming ESMO data release: “Where we can add Jeeva to regular standard of care, regular doses, regular schedule, of nivolumab plus FOLFOX. Without modifying it, it's well tolerated, and the efficacy it's, you know, it's it's very notable, and you'll see that. “
***Not mentioned here, but TJ Biopharma will pay
$80 million to IMAB when milestones reached. TJ going public at expected 1 billion market cap. IMAB owns 15% of TJ.
